Monday, 23 May 2011

Europe backs MS drug in change of tack

Source: The MS Trust:
Reversing an earlier decision, European regulators have recommended approving Acorda Therapeutics Inc's drug Fampyra, which is designed to improve the walking ability of patients with multiple sclerosis.
Acorda shares jumped 21 percent to $32.33 in premarket trading on Friday  For more click here.